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Abstract 
PURPOSE: To evaluate the plasma and tissue pharmacokinetics, safety and toxicity following intra-arterial 
hepatic artery administration of Vandetanib (VTB)-eluting Radiopaque Beads (VERB) in healthy swine. 
MATERIALS AND METHODS: In a first phase, healthy swine were treated with hepatic intra-arterial 
administration of VERB at target dose loading strengths of 36 mg/mL (VERB36), 72 mg/mL (VERB72) and 120 
mg/mL (VERB120). Blood and tissue samples were taken and analysed for VTB and metabolites to determine 
pharmacokinetic parameters for the different dose forms over 30 days. In a second phase, animals were 
treated with unloaded radiopaque beads or high dose VTB loaded beads (VERB100, 100 mg/mL). Tissue 
samples from embolized and non-embolized areas of the liver were evaluated at necropsy (30 and 90 days) for 
determination of VTB and metabolite levels and tissue pathology. Imaging was performed prior to sacrifice 
using multi-detector computed tomography (MDCT) and imaging findings correlated with pathological 
changes in the tissue and location of the radiopaque beads.  
RESULTS: The peak plasma levels of VTB (Cmax) released from the various doses of VERB ranged between 
6.19-17.3 ng/mL indicating a low systemic burst release. The plasma profile of VTB was consistent with a 
distribution phase up to 6 h after administration followed by elimination with a half-life of 20-23 h. The AUC 
of VTB and its major metabolite N-desmethyl vandetanib (NDM VTB) was approximately linear with the dose 
strength of VERB. VTB plasma levels were at or below limits of detection two weeks after administration. In 
liver samples, VTB and NDM VTB were present in treated sections at 30 days after administration at levels 
above the in vitro IC50 for biological effectiveness. At 90 days both analytes were still present in treated liver 
but were near or below the limit of quantification in untreated liver sections, demonstrating sustained release 
from the VERB. Comparison of the reduction of the liver lobe size and associated tissue changes suggested a 
more effective embolization with VERB compared to the beads without drug. 
CONCLUSIONS: Hepatic intra-arterial administration of VERB results in a low systemic exposure and 
enables sustained delivery of VTB to target tissues following embolization. Changes in the liver tissue are 
consistent with an effective embolization and this study has demonstrated that VERB100 is well tolerated with 
no obvious systemic toxicity. 
Key words: Vandetanib-eluting Radiopaque Beads, pharmacokinetics, safety and toxicity  
Introduction 
Drug Eluting Beads (DEBs) are controlled release 
microspherical devices that are used for sustained 
locoregional delivery of chemotherapeutic agents to 
various tumor types [1-4]. As compared with systemic 
delivery, they are associated with a decrease in the 
systemic circulation of the antineoplastic, an increase 
of drug concentration in target tissue and an extended 
presence in the tumor [5, 6]. DEBs are finding 
increasing use in the treatment of hepatic 
malignancies by intra-hepatic arterial administration 
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by a procedure known as transarterial 
chemoembolization (TACE) [7]. This procedure is in 
itself a combination therapy, which induces oxygen 
and nutrient deprivation to the tumor by occluding 
the feeding blood vessels, whilst providing for a 
concomitant sustained delivery of a high local dose of 
chemotherapy. DC Bead™ is the most widely studied 
DEB and is approved for loading with doxorubicin 
(DEBDOX) for the treatment of patients suffering 
from hepatocellular carcinoma (HCC, primary cancer 
originating in the liver) [5, 8-10]; whereas for those 
suffering from colorectal cancer metastases (mCRC) to 
the liver, may be treated with DC Bead™ loaded with 
irinotecan (DEBIRI) [11-15]. It has also been 
demonstrated that it is possible to administer DEBs by 
directly injecting them at the diseased site, for 
instance in pre-clinical animal models of peritoneal 
carcinomatosis [4], glioblastoma [2, 16] and pancreatic 
cancer [3, 17], although this is not currently within 
any of the DEB approval indications.  
Although DEBs offer an effective locoregional 
anticancer treatment with significant reductions in 
drug-related side effects, the fact remains that in 
many patients tumor growth will reoccur and their 
disease will ultimately progress. In an attempt to 
address this limitation, we explored the possibility of 
loading DEBs with newer small-molecule antitumor 
agents which have been designed to specifically target 
motifs on or within tumor cells in order to block 
signalling for pro-survival pathways that are 
responsible for cancer cell proliferation, 
proangiogenesis and metastasis. For instance, the 
multi-target kinase inhibitor (MTKi) sorafenib that 
targets both RAF and vascular endothelial growth 
factor receptor (VEGFR), improves overall survival of 
advanced HCC patients [18, 19] and is now the 
recommended treatment in this population. The 
inhibitor of epidermal growth factor receptor (EGF) 
erlotinib, has shown modest anti-tumor effects in 
patients with advanced HCC [20]. There is in general 
however, a significant issue of adverse side effects 
related to the systemic exposure of these types of 
agents [21-23] and therefore intra-arterial delivery 
from a DEB could be a feasible approach. Sunitinib 
has been successfully loaded into DC Bead™ [24, 25] 
and although significant antitumoral efficacy of the 
Sunitinib-eluting Beads was observed in the VX2 
rabbit tumor model [26], serious issues concerning 
systemic toxicity of sunitinib (18.5% death due to drug 
toxicity) [27] has led to exploring alternative 
candidates. 
 Vandetanib (VTB) is a MTKi targeting both 
VEGFR and EGFR, approved for the treatment of 
advanced medullary thyroid cancer [28-31]. It binds 
covalently to the cysteine residues of the TK domain 
and prevents binding of ATP, phosphorylation of the 
TK dimer and initiation of subsequent downstream 
signalling pathways. Xenograft studies confirm that 
VTB has activity across a number of different tumor 
types as a single agent in the dose range 25-50 mg/kg 
[32] and the drug recently demonstrated a good safety 
profile but limited efficacy compared to placebo in 
HCC [33]. In a randomized, double-blind, parallel 
group, multi-center, phase II study to assess the 
efficacy and safety of either 100 mg or 300 mg daily 
oral dose of VTB versus best supportive care (BSC) in 
patients with inoperable HCC, there were no 
significant differences in tumor stabilization rate (total 
of complete response, partial response and stable 
disease rates after 16 weeks), although there was some 
suggestion of a possibility of a benefit in overall 
survival. There were however, significant adverse 
events including diarrhoea, rash, GI haemorrhage and 
QT prolongation associated with the systemic 
exposure, which might be overcome by DEB delivery. 
We have recently reported on the preparation and 
characterization of a Vandetanib-eluting Radiopaque 
Bead (VERB) [34], which has also demonstrated 
efficacy in the VX2 tumor model (unpublished data). 
Here we report on the pharmacokinetics and safety of 
a preloaded version of VERB in a healthy swine liver 
embolization model, in preparation for first in human 
clinical evaluation. 
Materials and Methods 
Vandetanib-eluting Radiopaque Bead 
Preparation 
Vandetanib API (VTB, AstraZeneca, UK) was 
dissolved at approximately 20 mg/mL in 
hydrochloric acid (0.1 M) to aid the solubilization of 
the drug. 1.2 mL of Radiopaque Beads (ROB) [35] 
(Biocompatibles UK Ltd, Farnham, UK) was 
dispensed into a 10 mL glass vial (SCHOTT, Type 1), 
the packing solution was removed and beads were 
loaded with target doses of 36, 72 or 120 mg VTB 
using the appropriate volume of the stock solution. 
Drug loading was performed with shaking for 2 hrs 
for 36 and 72 mg samples, and overnight for 120 mg 
samples. Loading dose was determined by washing 
the beads with purified water and analysing the 
washing solution by HPLC. 1 mL of purified water 
was added to the drug loaded beads and the beads 
were frozen at -20˚C for approximately 2 hours. 
Loaded beads were lyophilized overnight in a 
benchtop freeze-drier (Heto Drywinner). The 
lyophilized beads were sealed with rubber bungs 
(Bromobutyl stopper, Daikyo), crimped and gamma 
sterilized at 25 kGy dose (Synergy Health).  
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Size Characterization of Vandetanib-eluting 
Radiopaque Beads 
The lyophilized beads were hydrated with 1.5 
mL purified water and left for 30 minutes to hydrate. 
The volume of beads was determined by transferring 
them to a 5 mL measuring cylinder and reading the 
sedimented volume. Bead morphology was observed 
under an Olympus BX50 optical microscope at X 10 
magnification. The diameter of 200 beads per vial was 
measured.  
Hepatic Arterial Embolization with 
Vandetanib-eluting Radiopaque Beads 
This evaluation was performed in a swine liver 
embolization safety model [36, 37] at MPI Research 
Inc. (Mattawan, Michigan, USA) using male 
experimentally naïve domestic Yorkshire crossbred 
swine (farm pigs, weights 53.5 – 66.5 kg at 
randomization). The study conformed to USDA 
Animal Welfare Act (9 CFR parts 1, 2 and 3) and the 
‘Guide for the Care and Use of Laboratory Animals’, 
Institute of Laboratory Animal Resources, National 
Academy Press, Washington, D.C, 2011. 
Study Design 
This study was designed in two phases: a 30 day 
study to evaluate pharmacokinetics and tissue levels 
of drug from three different dose levels of beads, and 
a second phase designed to look at histopathology, 
imaging and tissue levels at 90 days from one fixed 
dose (Table 1). For phase one, when the animal was 
administered with the full 1 mL dose volume of beads 
the actual dose of VTB was either: 36 mg, 72 mg, or 
120 mg. These groups were denoted as VERB36, 
VERB72 and VERB120 and three randomized animals 
were treated per group. Delivery of up to 1 mL of 
beads was anticipated to achieve near-stasis of a third 
to a half of the liver volume. The final volume 
delivered was based upon intra-procedural imaging 
feedback obtained during the administration 
procedure.  
 
Table 1. Outline of the two study phases 
 Phase One Study 
30 Days 
Phase Two Study 
30/90 days 
Group OVTB VERB36 VERB72 VERB120 ROB VERB100 
Target Drug 
Dose (mg) 
31,500 36 72 120 0 100 
Mean Bead 
Diameter (µm) 
NA 93.1 91.7 92.4 94.7 84.9 
Number of 
Animals 
3 3 3 3 3/3 4/4 
 
An oral gavage group (OVTB) was included to 
allow for pharmacokinetic comparison of the current 
clinical route for VTB therapy (oral route) versus 
intra-arterial delivery of drug loaded beads (n=3). A 
dose level of 21 mg/kg/day was selected based upon 
allometry, as this was predicted to provide drug 
plasma levels similar to those seen for humans 
receiving a 300 mg clinical dose via oral route [38].  
For phase two, animals were treated with either 
the unloaded radiopaque bead (ROB, n=6) or 
VTB-beads loaded with 100 mg/mL (denoted 
VERB100, n=8). At 30 days post administration, half 
of the animals in each group were imaged using 
Multi-Detector Computed Tomography (GE VCT 
Slice CT scanner) and then sacrificed in order to 
undertake histopathology analysis and tissue drug 
and metabolite levels. Imaging characteristics were as 
follows: 1.3 mm slice thickness, 300 mA, 120 kV and 
field of view 36 x 36 cm. The same process was 
repeated for the remaining half of the groups at 90 
days post administration.  
Swine Hepatic Embolization Procedure 
The vial of lyophilized beads was rehydrated in 
4mL of sterile water, gently swirled and left for 30 
minutes to rehydrate. The beads were mixed 1:19 with 
Omnipaque 350™ and suspended by transferring 
between two syringes through a 3-way stopcock. Bead 
suspension was aliquoted into a 3mL syringe for 
delivery through the microcatheter to allow for better 
control and re-suspended regularly to prevent 
sedimentation. 
A sheath was placed (Avanti 7F) in the femoral 
artery of the pig and under fluoroscopic guidance 
using an OECD 9900 Fluoroscope, a radio-opaque 
guidewire (Luge™ 0.014” x 182 cm (Boston Scientific 
Corp.) or Emerald® 0.35 inches (Cordis Corp.) was 
passed through the introducer into the femoral artery. 
A 4 Fr Cobra 2 catheter (AngioDynamics Inc.) was 
then positioned in the celiac axis and a celiac 
angiogram obtained by injecting contrast media. A 2.7 
Fr microcatheter (Progreat®, Terumo Japan) was then 
advanced in the hepatic artery branch chosen because 
it fed around 50% of the liver volume. The guidewire 
was subsequently removed and contrast media was 
used to capture an angiogram of the lobe(s). With the 
catheter in position and an appropriate target location 
identified, the test article was administered slowly 
under continuous fluoroscopy, evaluating changes in 
vascular flow rate and appearance of reflux or 
non-target embolization of the beads (inferred from 
visible contrast flow).  
The bead suspension was slowly administered 
under fluoroscopic guidance until the maximum 
volume was administered for all animals. Dosing 
occurred in the left lateral lobe or left median lobe for 
all animals. At the end of the embolization, bead 
suspension remaining within the micro-catheter was 
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flushed with saline prior to removing the 
micro-catheter. Pre- and post-embolization DSA 
images were used to document embolization effect 
(Table 2). Output cine fluoro loops and angiograms 
were used to assess the extent of embolization. 
Vascular flow was graded post-embolization to cover 
the range from complete occlusion to non-occlusion as 
indicated in Table 2. After all images were obtained, 
all guides, catheters, and the sheath were removed. 
The femoral artery was ligated. The muscle and 
subcutaneous tissues were closed with absorbable 
suture, and the skin was closed with skin glue. 
Vascular access site observations were performed 
daily up to Day 8 following intervention for signs of 
infection, inflammation, and general integrity.  
 
Table 2. Outcome of bead embolization procedures 
Group Study Vascular 
Flow 
Score* 
Average Bead 
Suspension 
Delivered 
(mL) 
Average 
Sedimented 
Bead Volume 
Delivered (mL) 
Average Drug 
Dose 
Administered 
(mg) 
VERB36 Phase 
One 
2(3) 18.833 0.94 30.9 
VERB72 Phase 
One 
1(2), 2(1) 16.333 0.82 58.8 
VERB120 Phase 
One 
1(3) 19.167 0.96 115.0 
ROB Phase 
Two 
1 (3), 
2(3) 
20.000 1.0 NA 
VERB100 Phase 
Two 
1(6), 2(2) 19.538 0.98 97.7 
*(1=slow antegrade flow in the embolized artery beyond the point of obstruction 
without perfusion distal to the occlusion; 2= slow antegrade flow in the embolized 
artery beyond the point of obstruction with partial perfusion or full perfusion with 
slow flow distal to the occlusion; Number in brackets = number of animals with this 
score) 
 
Clinical Observations and Measurements 
A detailed clinical examination of each animal 
was performed at receipt, prior to randomization, and 
daily during the study. All animals were observed for 
morbidity, mortality, injury, and the availability of 
food and water twice daily. Body weights for all 
animals were measured and recorded at receipt, prior 
to randomization, and weekly during the study. 
Ophthalmoscopic examinations were conducted 
pre-test and prior to sacrifice and 
electrocardiographic monitoring was performed 
pre-test, throughout the procedure, 1 hour post 
administration, 20 hours post recovery from surgery 
and for 20 hours a few days prior to sacrifice. 
Investigation of Vandetanib and Metabolite 
Plasma Pharmacokinetics and Tissue 
Concentrations 
Blood samples (approximately 1 mL) were 
collected from all animals in phase one via the jugular 
or other suitable vein for determination of the plasma 
concentrations of the test article, vandetanib (VTB), 
and the metabolites, N-desmethyl vandetanib (NDM 
VTB) and vandetanib N-oxide (VTB-NO). 
Concentrations of an unknown metabolite were also 
investigated. Samples were collected pre-test, 5 and 
20 minutes post-dose, and 1, 2, 6, 24, 72 hours 
post-dose on Day 0, and once on Days 5, 7, 14, 21, and 
29. Projected collection times for embolized animals 
were based on the completion time of dosing (after 
flush). The animals were not fasted prior to blood 
collection, with the exception of the intervals that 
coincided with fasting for clinical pathology 
collections. Samples were placed in tubes containing 
lithium heparin as an anticoagulant. The blood 
samples were collected on ice and centrifuged under 
refrigeration. Plasma samples were stored frozen 
at -60 to -90°C until analysis (York Bioanalytical 
Solutions Ltd., United Kingdom).  
Liver sections (approximately 3 x 5 g each) were 
collected from each liver lobe (treated and untreated 
areas where treatment was with embolization) for 
determination of the tissue concentrations of the test 
article and the metabolites. High resolution X-ray 
images were used to collect the representative 
samples from the treated areas of the liver. The 
samples from the treated lobe were taken and 
identified as proximal, middle, and distal to the 
approximate area of bead administration. The 
samples from the untreated lobes were taken and 
identified in a similar manner (i.e., proximal was the 
approximate area where the main arterial blood 
supply entered that lobe, distal was taken from the 
periphery of the lobe, and the middle area sample was 
taken mid-way between the other two samples). The 
samples were wrapped in foil and snap frozen in 
liquid nitrogen. The samples were labeled with the 
animal number and the liver lobe identification. The 
tissue samples were stored frozen at -70 to -90°C until 
shipped on dry ice to York Bioanalytical Solutions 
Ltd., United Kingdom, for analysis.  
VTB, VTB-NO and NDM VTB metabolite 
concentrations in swine plasma and liver were 
determined using solid phase extraction followed by 
liquid chromatography (Acquity iClass/Shimadzu 
Nexera) coupled to tandem mass spectrometry (MDS 
API5000) using turbospray in positive ion, multiple 
reaction monitoring mode. Separation was achieved 
using a 5 mL injection into a Thermo Accucore HILIC 
50 x 3 mm 2.6 µm analytical column run at 40°C, using 
formic acid (0.2 %) in acetonitrile: water: ammonium 
formate (1 M) mobile phases at 0.6 mL/min. VTB 
together with various metabolites and labelled 
analytical/internal standards (purity 99.1 – 100 %, 
AstraZeneca) were used as reference standards for the 
chromatography. 
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Individual VTB, NDM VTB, unknown 
metabolite, and VTB-NO concentration-time profiles 
from OVTB, VERB36, VERB72, or VERB120-treated 
animals were analyzed using model-independent 
methods. Toxicokinetic parameters were obtained for 
each animal following the first dose administration. 
Concentrations less than the lower limit of 
quantitation (LLOQ < 0.100 ng/mL) were reported as 
and set to zero in the calculations. Nominal times 
were used for toxicokinetic data analysis. For each 
animal, the following toxicokinetic parameters were 
determined: maximum observed plasma 
concentration (Cmax), time of maximum observed 
plasma concentration (Tmax), and area under the 
plasma concentration-time curve (AUC). The AUC 
from time 0 to 24 hr (AUC0-24hr) and from time 0 to the 
time of the final quantifiable sample (AUCTlast) were 
calculated by the linear trapezoidal method for all 
animals with at least three consecutive quantifiable 
concentrations. Half-life values (T1/2) were reported 
for individual plasma concentration-time profiles that 
had sufficient plasma concentrations in the terminal 
elimination phase (at least three samples not 
including Tmax) and an adjusted R2 of ≥ 0.9. Additional 
toxicokinetic parameters calculated were clearance 
(CL/F), and volume of distribution (Vz/F). The 
fraction of dose absorbed (F) was not determined; 
therefore Vz/F and CL/F were not normalized for the 
fraction of dose absorbed.  
Evaluation of Vandetanib-eluting Radiopaque 
Bead Imaging  
Thirty day post-embolization CT scans were 
performed on Phase One animals without 
administration of IV contrast and were available for 
review for all twelve animals. In Phase two, CT scans 
were performed on all animal after administration 
(Day 0) and prior to necropsy (Either Day 30 or 90). 
CT images from both phase one and two studies were 
analyzed to document location, distribution and level 
of radiopacity of the embolized beads. Specifically, 
the CT scans were reviewed for the following: i) CT 
visibility of unloaded and drug loaded beads, ii) 
distribution of beads within the liver, iii) approximate 
area/volume of liver embolized, and iv) extrahepatic 
non target embolization in adjacent organs including 
the stomach, spleen, pancreas and small bowel, 
specifically the duodenum, and in the visualized 
lungs.  
Pathological Analysis of the Effects of 
Vandetanib-eluting Radiopaque Bead  
Necropsy examinations were performed on the 
phase two animals under procedures approved by a 
veterinary pathologist on animals at the scheduled 
necropsies (Day 30 and Day 90). The animals were 
euthanized by an intravenous injection of sodium 
pentobarbital solution under Telazol® sedation, 
followed by exsanguination via transection of the 
femoral vessels. The animals were examined carefully 
for external abnormalities including palpable masses. 
The skin was reflected from a ventral midline incision 
and any subcutaneous masses were identified and 
correlated with antemortem findings. The abdominal, 
thoracic, and cranial cavities were examined with 
special attention paid to the liver, associated 
vasculature, surrounding tissues, gallbladder, hepatic 
bile ducts, gastrointestinal tract, lungs, heart, kidney, 
spleen, and brain for abnormalities. The organs were 
removed, examined, and, where required, placed in 
fixative for subsequent analysis for tissue 
abnormalities and off-target embolization. All 
designated tissues were fixed in neutral buffered 
formalin. The liver was submitted for high resolution 
X-ray prior to sectioning to aid in identification of the 
treated lobe. Microscopic examination of fixed 
hematoxylin and eosin-stained paraffin sections was 
performed on protocol-designated sections of tissues. 
Three sections of treated liver were examined for all 
animals. The slides were examined by a 
board-certified veterinary pathologist. Special stains 
were used by the pathologist as needed to aid in the 
diagnosis of specific lesions and representative 
photomicrographs of tissue sections were taken.  
Results 
Embolization Procedure with 
Vandetanib-eluting Radiopaque Beads 
In the phase one study VERB36, VERB72, or 
VERB120 beads were successfully delivered under 
fluoroscopic guidance until near stasis was achieved 
or angiographic evidence of the potential for 
extra-hepatic non target embolization was observed. 
Almost the entire dose was administered to all 
animals with the exception of animal in the VERB72 
group that received just 10 mL of volume (out of 20 
mL total) as the embolization was stopped due to 
angiographic evidence of the potential for 
extra-hepatic non-target embolization (Table 2). 
During administration, there was no evidence of 
beads settling or clogging within the catheter, 
extra-hepatic non-target embolization, or reflux 
exceeding 1 to 2 cm from the catheter tip. Following 
completion of embolization, vascular blood flow 
within the treated lobe of the liver was assessed to 
evaluate level of vascular occlusion.  
There were no abnormal clinical observations or 
vascular access site observations related to 
administration of the test article. The clinical findings 
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observed (e.g., abrasions, scabbed areas, lacrimation) 
are commonly seen in animals of this sex, age, and 
species. There were no test article-related body 
weights effects evident. Animals across all groups 
gained a similar percentage of weight (9 to 16%) 
during the course of the study from Week 1 until 
study termination (Week 4 or 5). VTB has some 
reported adverse effects on the eyes (corneal 
verticillata) and the heart (QTc prolongation and 
cardiac failure) [39] but here there were no abnormal 
ophthalmoscopic findings evident prior to necropsy 
and ECG parameters and heart rate were comparable 
across all groups.  
Investigation of Vandetanib and Metabolite 
Plasma Pharmacokinetics 
Plasma samples from the phase one study were 
successfully analyzed for concentrations of VTB, 
NDM VTB and VTB-NO. An unknown metabolite 
peak was also observed in the analysis, this peak had 
the same ion transition as VTB-NO and appeared to 
be present at levels well in excess of the N-oxide 
metabolite but is not reported in this analysis. This 
metabolite has not been reported in humans, mice or 
rats but has been observed during this study in swine 
and also in rabbits (unpublished data). 
Pharmacokinetic parameters were calculated for VTB, 
NDM VTB and VTB-NO and are shown in Table 3. 
Figure 1(a) shows that the Tmax (time to reach Cmax) is 
achieved within approximately 1 hour of treatment 
administration for the VERB groups and 
approximately 2 hours for OVTB given the dose 
difference (21 mg/kg). Figure 1(b) shows that the 
values of the area under the curve (levels of drug in 
the plasma over time) measured after either 24 hours 
(AUC0-24) or until the last quantifiable measurement 
was made (AUCTlast), are linearly correlated for both 
VTB and NDM VTB with the dose of VTB 
administered in the beads. 
Investigation of Vandetanib and Metabolite 
Tissue Concentrations 
Liver samples collected from the phase one 
study were successfully analyzed for concentrations 
of VTB, NDM VTB and VTB-NO (Table 4). The 
concentrations observed in all OVTB samples for VTB, 
and four OVTB samples for NDM VTB were reported 
as >75000 ng/g. These samples were analyzed with a 
dilution of 500-fold and it was beyond the scope of the 
validated range to increase the dilution further.  
From the phase two study, liver samples from 
the VERB100 group were successfully analyzed for 
concentrations of VTB, NDM VTB and VTB-NO 
(Table 5).  
Imaging Appearance of Embolized Livers 
All radiopaque beads, regardless of drug dose, 
administered during both the phase one and two 
studies were visible on fluoroscopy and DSA post 
embolization and contrast wash-out (Figure 2), and on 
CT (given their high attenuation) both with and 
without contrast. There was no detectable difference 
in visibility between the drug loaded bead groups at 
the three different drug concentrations in the phase 
one study (Figure 3). In all cases the beads could be 
seen in hepatic arteries within the embolized lobes, 
with relatively distal penetration consistent with the 
size of the beads and lack of proximal aggregation.  
 
Table 3. Pharmacokinetic parameters for the Phase One Study 
Group N Cmax 
(ng/mL) 
Cmax/Dose 
(kg*ng/mL/mg) 
Tmax 
(hr) 
AUC0-24hr 
(hr*ng/mL) 
AUC0-24/Dose 
(hr*kg*ng/mL/mg) 
AUCTlast 
(hr*ng/mL) 
Cl/F 
(mL/hr/kg) 
Vz/F 
(mL/kg) 
T½ 
(hr) 
VTB 
OVTB 3 216 ± 33.0 10.3 ± 1.57 2 (2-6) 2860 ± 488 136 ± 23.2 48,300 ± 6670 NA NA NA 
VERB36 3 6.19 ± 1.56 11.3 ± 3.03 1 (1-1) 72.8 ± 14.4 132 ± 21.6 143 ± 33.4 3780 ± 637 106,000 ± 
18,100 
19.7 ± 3.95 
VERB72 2 15.8 (NA) 13.7 (NA) (1-2) 174 (NA) 151 (NA) 312 (NA) 3690 (NA) 120,000 22.6 (NA) 
VERB120 3 17.3 ± 3.65 8.63 ± 1.74 1 (1-1) 246 ± 68.5 123 ± 37.7 501 ± 185 4320 ± 1480 130,000 ± 
29,700 
21.5 ± 2.87 
NDM VTB 
OVTB 3 126 ± 25.3 6.02 ± 1.2 696 (504-696) 417 ± 45.9 19.9 ± 2.18 51,800 ± 5040 NA NA NA 
VERB36 3 0.565 ± 0.146 1.03 ± 0.304 24 (24-24) 7.86 ± 0.976 14.3 ± 2.30 40.9 ± 4.35 NA NA NA 
VERB72 2 0.951 (NA) 0.824 (NA) (24-72) 16.2 (NA) 14.1 (NA) 89.7 (NA) 11,800 (NA) 824,000 (NA) 48.5 (NA) 
VERB120 3 1.69 ± 0.254 0.843 ± 0.150  24 (24-24) 23.0 ± 5.23 11.5 ± 2.93 151 ± 46.6 12,800 ± 
4020 
818,000 ± 
301,000 
43.7 ± 5.52 
VTB-NO 
OVTB 3 1.35 ± 0.259 0.0643 ± 0.0124 2 (2-2) 15.4 ± 0.739 0.732 ± 0.0352 246 ± 32.1 NA NA NA 
VERB36 3 0.154 ± 0.02 0.282 ± 0.0468 0.083 (0.083-0.333) NA NA 0.317 (NA) NA NA NA 
VERB72 2 0.384 (NA) 0.329 (NA) (0.083-2) NA NA 0.404 (NA) NA NA NA 
VERB120 3 0.374 ± 0.065 0.186 ± 0.0345 0.083 (0.083-0.083) NA NA 1.2 ± 0.576 NA NA 1.0 ± 3.39 
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Figure 1. (a) Plasma levels of VTB for the first 24 hours following treatment with OVTB, VERB36, VERB72 and VERB120; (b) Areas under the curve (AUC) between 
T=0 and 24 hours (AUC0-24) and T=0 and the last quantifiable data point (AUCTlast) for VTB and NDM VTB versus VTB dose administered. (Error bars are omitted 
for clarity, see Table 3 for standard deviations). 
 
Table 4. Analyte concentrations in liver samples from the phase one study (taken from embolized and non-embolized regions for the 
bead-treated groups) at day 30 post-embolization. Data shown are the mean with the range in brackets.  
 
Group 
Analyte Concentration (ng/g) in Liver Sample Section 30d 
VTB NDM VTB VTB-NO 
OVTB (n=6) >75,000 >10,000 (n=4 > 75,000) 5.14 (3.28-9.67) 
 Embolized 
(n=3) 
Non-embolized 
(n=3) 
Embolized 
(n=3) 
Non-embolized 
(n=3) 
Embolized 
(n=3) 
Non-embolized 
(n=3) 
VERB36 103.0 ± 124.2 47.1 ± 64.9 63.4 ± 96.7 35.1 ± 48.0 0.255 <LLOQ 
VERB72 34.5 ± 42.2 4.54 ± 2.7 3.15 ± 2.05 3.68 ± 1.90 0.239 <LLOQ 
VERB120 167.0 ± 158.8 2.86 ± 0.6 6.26 ± 3.16 1.91 ± 0.63 1.61 <LLOQ 
(BLQ=Below Lower Limit of Quantification; <LLOQ = <Lower Limit of Quantification (0.150)) 
 
 
Table 5. Analyte concentrations in liver samples from the phase 
two study (mean of the three liver locations, ±SD), embolized and 
non-embolized regions treated with VERB100 at day 30 and 90 
post-embolization (NA= not applicable). 
 
Analyte 
30 Days  90 Days 
Embolized 
(n=12) 
Non-embolized 
(n=12) 
Embolized (n=9) Non-embolized 
(n=9) 
VTB  105.8 ± 249.1 0.585 ± 0.222 8.55 ± 7.84 0.121 ± 0.106 
(n=4) 
NDM 
VTB 
6.31 ± 8.01 0.478 ±0.180 1.73 ± 1.67 NA 
VTB-NO 0.640 ± 0.961 
(n=8) 
NA NA NA 
 
 
In the phase two study, all animals administered 
with control or VERB100 bead suspension received 
greater than 92% of the full dose prepared for 
administration (dose volume ranging from 18.5 to 20 
mL). By fluoroscopic estimation, approximately 50 % 
of the liver volume was embolized in all animals. 
There was also no definitive difference in the 
distribution of the beads in the embolized liver. The 
appearance did not change from the Day 0 to the Day 
30 or Day 90 repeat CT examinations (Figure 4).  
No biliary ductal dilatation was noted on the 
Day 0 CTs of unloaded or drug loaded beads with 
targeted lobe sizes similar between both. Biliary 
dilatation was seen on 4/4 Day 30 CTs of the 
VERB100 group and 0/3 the Day 30 CTs of the ROB 
control group. The Day 90 CTs of the VERB100 group 
show 2/3 with biliary dilatation. The Day 90 CTs of 
the unloaded control group show 2/3 with biliary 
dilatation. Lobe size of both control group and 
VERB100 group were compared to initial appearance 
and adjacent non-targeted lobes. There was a reduced 
size of the targeted lobe in 6/7 VERB100 group 
(Figure 5(b)). The control group demonstrated 
decreased size in 0/6. This was noted to be present on 
Day 30 and Day 90 CTs. Areas of decreased perfusion 
on initial CT demonstrate decreased size on follow up 
CT. Again, the finding can be attributed to more 
effective embolization which would decrease lobule 
and hence lobe size.  
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Figure 2. (a) DSA pre-embolization showing arteries to be embolized (yellow arrows); (b) Fluoroscopic image post-embolization and contrast wash-out showing 
VERB100 in arteries (red circle); (c) DSA post-embolization showing shadowing imaging artefact from the radiopaque beads in the arteries (red arrows). Catheter tip 
position is shown in the yellow circle and the blue arrow points to reflux of contrast in a more proximal arterial branch related to distal embolization. 
 
Pathological Findings following Embolization 
Injected beads were present in sections of treated 
liver in all animals of the phase two study groups, 
with no beads seen in the untreated sections of liver. 
Changes were mostly segmental affecting only 
portions of the sections examined, with beads being 
more abundant in the intermediate and distal sections 
compared to the proximal sections of treated liver. 
After staining and processing, the beads appeared as 
deep blue spheres present in small vessels in portal 
spaces. Occasionally the beads were displaced from 
the tissue during sectioning, leaving a round hole in 
the section where they were previously located (e.g. 
Figure 6 (d)). 
 Interlobular fibrosis was observed for both 
unloaded (1/3 animals, Figure 6(a)) and the VERB100 
group (4/4 animals, Figure 6(b)) at 30 days and this 
persisted at 90 days (3/3 and 2/3 animals 
respectively). This was often associated with bile duct 
hyperplasia, encircling lobules that were reduced in 
size, resulting in a macroscopic reduction in the size 
of the treated liver lobe (Figure 6(b, c)). Reduced 
lobule size in the treated sections of liver in the 
VERB100 group (3/4 animals) was characterized by 
smaller lobules with disorganized trabeculae but no 
evidence of hepatic degeneration. The finding 
correlated to the reduced lobe size noted following 
radiologic evaluation (Figure 5(b)). The shrunken 
lobules were lined by small bile ducts extending from 
the portal spaces (identified as bile duct hyperplasia, 
3/4 animals) and/or variably sized bundles of fibrosis 
(interlobular fibrosis, 4/4 animals, Figure 6(c)). In 
addition, large bile ducts were occasionally dilated 
(Figure 6(b)) and were surrounded or had 
inflammatory infiltrate in their lumen (2/4 animals, 
Figure 6(d)). The bile duct dilation was also noted 
following radiologic evaluation (Figure 5(b)). None of 
these treatment-related findings were present in the 
untreated liver section and are consistent with 
impaired blood flow with subsequent necrosis and 
regeneration.  
 
 
Figure 3. 30 Day coronal thin MIP reformations from CT acquisition showing 
the distribution of beads in one representative animal per group. There is no 
difference in CT visualization or density between VERBs of different drug doses. 
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Figure 4. MDCT axial images of the liver of VERB100 treated animals at (a) 1 hour post-embolization and (b) 90 Days post-embolization, showing no discernible 
differences in bead visibility. 
 
Figure 5. (a) MDCT axial image of portal venous phase post contrast, 1 hour post-embolization with VERB100, yellow arrows point to areas of decreased hepatic 
parenchymal enhancement; (b) MDCT axial image of portal venous phase post contrast, red arrows indicate dilated bile ducts, yellow arrows show the reduced left 
liver lobe size 30 days post-embolization. 
 
On day 90 of the phase two study, interlobular 
fibrosis (3/3 animals), reduced lobule size (3/3 
animals), and/or bile duct hyperplasia (2/3 animals) 
were present in the treated liver of the unloaded 
control group. The interlobular fibrosis was present in 
the treated liver sections of all the unloaded control 
group animals compared to only one animal on day 
30 of the study (Figure 7(a)). The interlobular fibrosis 
was associated with bile duct hyperplasia and/or 
decreased lobule size in the unloaded control group 
and similar to what was observed on day 30 in the 
VERB100 group. The reduced lobule size and bile 
duct dilatation/ inflammation were resolved in the 
treated liver sections in the VERB100 group, whereas 
bile duct hyperplasia (2/3 animals) and interlobular 
fibrosis (2/3 animals) although less severe, were still 
present in the treated sections compared to the 
untreated liver (Figure 7(b-d)). 
Discussion 
Hepatic arterial embolization using VERB was 
shown to be feasible and safe. For the 
pharmacokinetic evaluation of VTB and metabolites 
in the plasma, it was observed that there was a 
surprisingly low burst release of VTB in the first hours 
post-administration (Cmax ranging from 6.19-17.3 
ng/mL for the three doses). Assuming a blood 
volume of around 3.9 L in a 60 kg animal and minimal 
metabolism and elimination in the first hour, this 
represents <0.1 % of the loaded drug dose on the 
VERB. The normalized AUC0-24hr of the different 
VERB dose groups in phase one were 136, 132, 151, 
and 123 hr*kg*ng/mL/mg, respectively. This 
indicates a linear relationship between dose and 
AUC0-24hr for all groups assuming that the oral dose is 
completely absorbed. The AUCTlast also showed a 
linear relationship with dose for the VERB groups. 
The mean elimination half-life values were very 
similar for the VERB groups at 19.7, 22.6, and 21.5 hr 
respectively, illustrating that the drug is eliminated 
slowly and has good opportunity to accumulate to 
effective levels in the targeted tissues. The same linear 
trend in AUC versus dose was also evident for the 
NDM VTB metabolite. The long Tmax for this 
metabolite in the OVTB group suggests that it 
accumulates on repeated administration which is 
consistent with its long half-life where measurable. 
The NDM VTB metabolite has similar inhibitory 
activity against VEGFR-1, VEGFR-2, EGFR and 
FGFR-1 compared to the parent compound, VTB-NO 
to a much lesser extent. [40] and the long-lived nature 
of these metabolites in the target tissue is useful from 
a locoregional efficacy perspective. 
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Figure 6. 30 Days post-embolization. (a) Clusters of unloaded control beads (yellow arrows) in the distal treated liver, with mild interlobular fibrosis (blue arrows) 
(x 1 magnification, scale bar = 2 mm). (b) VERB100 beads (yellow arrows) in the intermediate treated liver showing interlobular fibrosis, sometimes encircling reduced 
size lobules and with bile duct dilatation (red arrow) (x 1 magnification, scale bar = 2 mm). (c) VERB100 beads (yellow arrows) in the portal space, with interlobular 
fibrosis (blue arrows) and bile duct hyperplasia (green arrows) encircling reduced size lobules (x 4 magnification, scale bar = 500 µm). (d) VERB100 beads (yellow 
arrows) embedded within inflammatory infiltrate within the liver (purple arrow) (x 5 magnification, scale bar = 400 µm).  
 
Figure 7. 90 Days post-embolization. (a) Unloaded control beads (yellow arrows) with interlobular fibrosis (blue arrows) and bile duct hyperplasia (green arrows) 
around reduced size lobules (x 1 magnification, scale bar = 2 mm). (b) VERB100 beads (yellow arrows) in the intermediate treated liver with mild bile duct hyperplasia 
(green arrows) (x 1 magnification, scale bar = 2 mm). (c) VERB100 beads (yellow arrows) integrated into the intermediate treated liver tissue with no signs of reaction 
or inflammation and mild interlobular fibrosis (blue arrows) (x 4 magnification, scale bar = 500 µm). (d) Untreated portion of the liver of an VERB100 group animal 
for comparison, showing normal connective tissue separating lobules and normal liver tissue appearance (x 2 magnification, scale bar = 1 mm).  
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The low burst release and Cmax observed for 
VERB can be compared with the reported Cmax levels 
of 42.8-651 ng/mL for doxorubicin loaded DC Bead™ 
(1 mL administration of 100-300 µm and 700-900 µm 
sized beads loaded at 37.5 mg/mL) in a similar 
embolization model, which typically elutes 0.5-6 % of 
the loaded dose into the plasma in the first hours 
post-administration and is considered a slow and 
sustained release system [36]. This slow in vivo release 
of VTB is attributed to both the radiopaque bead 
platform, which has a more hydrophobic matrix that 
retards drug elution, and to the physicochemical 
properties of the drug, as its solubility is reduced at 
neutral pH [34]. These properties lead to minimal 
systemic exposure of drug when delivered from 
VERB, which is highly desirable when the drug is 
associated with potential severe adverse cardiac 
effects when delivered orally at higher doses. [39] 
When administered orally, levels of VTB and its 
metabolites in liver tissue were very high, as 
anticipated from the daily dosing and long half-life of 
the drug (19 days in humans). [41] This extended 
exposure increases the chances of prolonged QT 
interval, Torsades de pointes and sudden death and 
why local delivery of lower doses may be a strategy 
for overcoming these adverse events. When delivered 
in a locoregional manner via the beads, both the phase 
one and two studies demonstrated measurable levels 
of VTB and its main metabolite NDM VTB remaining 
in the liver tissue at 30 days, with much higher levels 
being found in the targeted embolized than 
non-embolized tissues. There was no obvious 
relationship regarding drug levels and location of the 
tissue sample relative to the point of delivery from the 
catheter. Most striking was the presence of both VTB 
and NDM VTB in liver samples at 90 days post 
administration, which demonstrates the extended 
release nature of the drug-eluting bead delivery 
platform. VTB has been shown to be a potent inhibitor 
of both VEGF-stimulated and EGF-stimulated human 
umbilical vein endothelial cell (HUVEC) proliferation 
in vitro with reported IC50 levels of 0.06 µM and 
0.17 µM respectively [32]. In this study we observe 
VTB tissue levels at 30 days in the range 0.073-0.352 
µM, which demonstrates that this controlled release 
system should release levels of drug for at least 1 
month sufficient to induce the desired anti-angiogenic 
effects on the tumor vasculature. Moreover, VTB has 
been shown to elicit a direct inhibition of tumor cell 
growth, most probably via inhibition of EGFR tyrosine 
kinase activity [42] and may be another mechanism by 
which locoregional delivery of VTB can induce an 
antitumor effect. 
Despite the increase in density due to the 
introduction of iodine species to provide radiopacity 
[35], VERBs were easily handled by suspension of the 
2 mL of hydrated beads in 18 mL of soluble contrast 
agent, followed by slow administration at a rate of 
around 1 mL of suspension per minute. The beads 
could be clearly seen on fluoroscopy as they 
accumulated in the hepatic vessels and the soluble 
contrast washed away (Figure 2) [43]. Despite this, 
some off-target embolization was expected as 
attempts were made to deliver the full dose of 1 mL of 
beads, which was achieved in most cases. The 
radiopacity of the VERB embolic device was shown to 
be useful not only during delivery for targeting the 
beads, but at follow-up by CT for identifying bead 
location and associated imaging findings such as 
decreased hepatic parenchymal enhancement in the 
treated locations, embolization-related lobe size 
reduction and bile duct dilation. Biliary dilatation is 
likely indicative of hepatic artery ischemia caused by 
the embolization, because the biliary ducts are 
supplied by hepatic arteries rather than portal vein 
blood supply. There was no obvious difference in the 
radiopacity between VERB with different drug doses 
used in the phase one study, despite the drug 
potentially contributing slightly to the overall 
radiopacity due to the presence of radiodense 
bromine atoms on the drug structure [34]. The 
radiopacity of the beads did not change over the 90 
day period confirming the stability of the device as 
demonstrated previously with this radiopaque 
platform [37]. 
Based on the histopathological evaluation, there 
were expected microscopic findings associated with 
hepatic embolization following intrahepatic 
administration of up to 1 mL of either the unloaded 
ROB or VERB100 beads. On day 30, findings in the 
treated liver of animals administered VERB100 beads 
consisted of reduced lobule size, bile duct 
hyperplasia, interlobular fibrosis, and bile duct 
dilatation/inflammation. By day 90, reduced lobule 
size and bile duct dilatation/inflammation were 
resolved in the treated liver sections, whereas bile 
duct hyperplasia and interlobular fibrosis were still 
present in the treated sections. On day 90, interlobular 
fibrosis, reduced lobule size, and/or bile duct 
hyperplasia were present in the treated liver in the 
unloaded control group. These findings suggest a 
more profound effect on the liver parenchyma with 
VERB100 beads, compared to unloaded control. The 
study also demonstrated that administration of 
VERB100 resulted in no obvious systemic toxicity 
following implantation. 
Conclusions 
VTB is a MTKi that has been successfully loaded 
onto a radiopaque drug-eluting bead platform with 
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the potential for locoregional administration to treat 
hepatic malignancies. Different doses of VTB were 
investigated in the first phase of this study and 
demonstrated low systemic exposure compared to 
oral dosing, with a linear relationship between the 
observed plasma AUC and the dose loaded into the 
beads. From the second phase of the study it is noted 
that no unexpected hepatic toxicities were seen, with 
pathological changes consistent with the effects of 
embolization of hepatic arterial vasculature, those 
effects appearing more pronounced when VERBs 
were delivered into the liver suggesting additional 
local effects from the drug. One limitation of the 
swine hepatic artery embolization model is that there 
is no tumor present and therefore the anti-cancer 
effects of the drug cannot be properly evaluated. The 
model does however, offer an indicator of the safety 
of such an investigational product in a large animal, in 
which a clinically-relevant dose of drug-loaded bead 
can be administered and its effects on healthy liver 
tissue determined. This model has also permitted the 
quantification of drug and metabolite levels over a 
sustained period of delivery and coupled with what is 
already known regarding the efficacy and mode of 
action of VTB, provides optimism that therapeutic 
levels of drug may be maintained in the liver over a 
period of at least a month following treatment. These 
findings support a First-in-Human evaluation of 
VERB for the locoregional treatment of hepatic 
malignancies. 
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